Deucravacitinib 6mg po qd

DRUG2 trials

Sponsors

Xi Tan, Peking University People's Hospital

Conditions

EczemaIdiopathic Inflammatory Myopathies (IIMs)JAK InhibitorPsoriasis

Unknown Phase

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

Enrolling by invitationNCT06999941

Xi TanEczema, JAK Inhibitor, Psoriasis

Start: 2025-04-24End: 2026-08-30Target: 50Updated: 2026-06-10

Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies

WithdrawnNCT07564271

Peking University People's HospitalIdiopathic Inflammatory Myopathies (IIMs)

Start: 2025-10-05End: 2026-10-01Updated: 2026-07-09